Interview with Dr. Jeffrey Conn

In a deal that goes beyond the traditional industry-academia partnership, Vanderbilt University, in Nashville, and Janssen Pharmaceutica, the mental health arm of Johnson & Johnson, have partnered to develop schizophrenia treatments.

The research lab of Jeffrey Conn, director of Vanderbilt's Program in Drug Discovery, will receive $10 million from an up-front payment and other funding from Janssen. The lab stands to receive further milestone payments during the three-year pact. Janssen gains an exclusive license to existing compounds that act on a neurotransmitter target and could license and develop future molecules discovered in the collaboration.

Read More: Unique Deal Reflects Novel Drug Discovery Program at Vanderbilt University


Annual Meeting

Program CoverThe ACNP Annual Meeting is one of the world's leading forums for the exchange of cutting edge scientific information about the brain, behavior, and psychotropic drugs.

ACNP Publications

Program CoverThe College offers a variety of Publications with the latest and most comprehensive research in psychopharmacology and related fields.

Research Discussions

This forum enables discussion of articles that have appeared in Neuropsychopharmacology. It is intended to stimulate scholarly interactions among researchers, and to help educate members of the public who are interested in psychiatric illness.